Use of Interferon-Inducible 2',5'-Oligoadenylate-Dependent RNase in the Diagnosis, Prognosis, and Treatment of Prostate Cancer


This invention pertains to the use of interferon-inducible 2',5'-oligoadenlyate-dependent RNase L in the diagnosis, prognosis and treatment of cancer, particularly prostate cancer. The inventors have identified a potential prostate cancer susceptibility locus, which has been designated HPC1 due to its putative link to hereditary prostate cancer. HPC1 may lead to an early, sensitive and accurate method for detecting cancer or a predisposition to cancer, especially prostate cancer, in a mammal. In addition, such claimed methods can be used to monitor onset and progression of cancer, as well as a patient's response to a particular treatment.

Inventors:

John Carpten (NHGRI)  ➽ more inventions...

Jeffrey Trent (NHGRI)  ➽ more inventions...

Patrick Walsh
Dietrich Stephan
Nina Nupponen (NHGRI)  ➽ more inventions...


Intellectual Property:
PCT Application No. PCT/US02/19516

Licensing Contact:
Admin. Licensing Specialist (ALS),
Email:
Phone:

OTT Reference No: E-196-2001-0
Updated: Nov 1, 2002